Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Non-cash Items (2022 - 2025)

Axsome Therapeutics (AXSM) has disclosed Non-cash Items for 4 consecutive years, with $919114.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 82.88% to $919114.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $919114.0 through Dec 2025, down 82.88% year-over-year, with the annual reading at $919114.0 for FY2025, 82.88% down from the prior year.
  • Non-cash Items hit $919114.0 in Q4 2025 for Axsome Therapeutics, down from $5.6 million in the prior quarter.
  • In the past five years, Non-cash Items ranged from a high of $198.4 million in Q1 2024 to a low of $919114.0 in Q4 2025.
  • Historically, Non-cash Items has averaged $64.5 million across 4 years, with a median of $5.5 million in 2024.
  • Biggest five-year swings in Non-cash Items: skyrocketed 5365.7% in 2023 and later plummeted 96.55% in 2025.
  • Year by year, Non-cash Items stood at $95.7 million in 2022, then tumbled by 95.27% to $4.5 million in 2023, then grew by 18.68% to $5.4 million in 2024, then crashed by 82.88% to $919114.0 in 2025.
  • Business Quant data shows Non-cash Items for AXSM at $919114.0 in Q4 2025, $5.6 million in Q3 2025, and $133.8 million in Q2 2025.